Advanced AAV Processing and Potency through Characterisation of Capsid and Payload Heterogeneity

Description

Enhancing adeno-associated virus (AAV) viral vector quality can significantly impact product efficacy and is essential to ensure patient safety. We invite you to join our team of experts for a deep dive into our AAV viral vector development expertise and showcase our recent breakthroughs.

In this webinar, our speakers will delve into how the characterisation of the contents and surface of AAV capsids has helped identify factors influencing charge heterogeneity, and, consequently, the potency of AAV products:

• We will first present how VP1 deamidation, which has been associated with a decrease in potency, is also connected to hydrophobicity

• We will investigate how production time within the bioreactor and AAV location inside or outside the cell affects capsid post-translational modifications and surface charge

• We will finally demonstrate the importance of reducing and controlling the level of intermediate (partially full) and empty capsids, which can impact product efficacy and have potential implications for patient safety

After the webinar, we will host a live Q&A session, providing attendees with the opportunity to ask questions directly to the presenters. We look forward to your participation.

Who Should Attend?

This webinar will appeal to professionals in the following fields or those having the following job titles:

• Biotechnology and pharmaceutical professionals

• Project Managers/Technical Experts

• Research & Development

• Cell and Gene Therapy Program Leaders

• Business Development

• Academics

What You Will Learn

Attendees will learn about:

• Negative charge due to deamidation and hydrophobicity are related and impact capsids separation

• Production duration and location of capsids at harvest affect AAV charge and potency

• How although intermediate capsids contribute to overall titer and are infectious, their payloads are not efficacious and thus considered a process-related impurity

Speakers: Sarah Laughlin-Toth - Senior Scientist II Analytical Development, Oxford Biomedica; Thomas Thiers - Scientist II Purification Sciences, Oxford Biomedica; Alex Meola - Associate Director, AAV Downstream Process Development, Oxford Biomedica.